

## DAFTAR PUSTAKA

- Adhitama, W., 2019. Evaluasi luaran klinis terapi antibiotika pada pasien anak rawat inap dengan infeksi saluran kemih di RSUP Dr. Sardjito Yogyakarta. Univ. Gadjah Mada.
- Ahmed, S., Wilcox, M.H., Kirby, A., 2020. Measuring outcomes in complicated intra-abdominal infections. *Curr. Opin. Gastroenterol.* 36, 1–4. <https://doi.org/10.1097/MOG.0000000000000591>
- Aliska, G., Setiabudy, R., Karuniawati, A., Sedono, R., Dewi, T.U., Azwar, M.K., 2017. Optimal Amikacin Levels for Patients with Sepsis in Intensive Care Unit of Cipto Mangunkusumo Hospital, Jakarta, Indonesia. *Acta Med Indones* 10.
- Alqarni, A., Kantor, E., Grall, N., Tanaka, S., Zappella, N., Godement, M., Ribeiro-Parenti, L., Tran-Dinh, A., Montravers, P., 2018. Clinical characteristics and prognosis of bacteraemia during postoperative intra-abdominal infections. *Crit. Care* 22. <https://doi.org/10.1186/s13054-018-2099-5>
- Alwarawrah, Y., Kiernan, K., MacIver, N.J., 2018. Changes in Nutritional Status Impact Immune Cell Metabolism and Function. *Front. Immunol.* 9. <https://doi.org/10.3389/fimmu.2018.01055>
- Arefian, H., Hagel, S., Fischer, D., Scherag, A., Brunkhorst, F.M., Maschmann, J., Hartmann, M., 2019. Estimating extra length of stay due to healthcare-associated infections before and after implementation of a hospital-wide infection control program. *PLOS ONE* 14, e0217159. <https://doi.org/10.1371/journal.pone.0217159>
- Armstrong, C., 2010. Updated Guideline on Diagnosis and Treatment of Intra-Abdominal Infections. *Am. Fam. Physician* 82, 694.
- Arshad, A., Rehman, S., Zaka, M., Tahir Mahmood, K., 2011. Rational Use of Amikacin in Children. *J. Pharm. Sci. Res.* 3.
- ATS, 2005a. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. *Am. J. Respir. Crit. Care Med.* 171, 388–416. <https://doi.org/10.1164/rccm.200405-644ST>
- ATS, 2005b. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. *Am. J.*

Respir. Crit. Care Med. 171, 388–416.  
<https://doi.org/10.1164/rccm.200405-644ST>

Bauer, L., 2008. *Applied Clinical Pharmacokinetics*. McGraw-Hill Education.

Best, E. J., Gazarian, M., Cohn, R., Wilkinson, M., Palasanthiran, P., 2011. Once-daily Gentamicin in Infants and Children 30, 827–832.  
<https://doi.org/10.1097/INF.0b013e31821e405d>

Best, Emma J., Gazarian, M., Cohn, R., Wilkinson, M., Palasanthiran, P., 2011. Once-daily gentamicin in infants and children: a prospective cohort study evaluating safety and the role of therapeutic drug monitoring in minimizing toxicity. *Pediatr. Infect. Dis. J.* 30, 827–832.  
<https://doi.org/10.1097/INF.0b013e31821e405d>

Botha, F.J., van der Bijl, P., Seifart, H.I., Parkin, D.P., 1996. Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient. *Intensive Care Med.* 22, 443–446.  
<https://doi.org/10.1007/BF01712162>

Bradley, J.S., Byington, C.L., Shah, S.S., Alverson, B., Carter, E.R., Harrison, C., Kaplan, S.L., Mace, S.E., McCracken, G.H., Moore, M.R., St Peter, S.D., Stockwell, J.A., Swanson, J.T., Pediatric Infectious Diseases Society and the Infectious Diseases Society of America, 2011. Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* 53, 617–630.  
<https://doi.org/10.1093/cid/cir625>

Brunton, L., Lazo, J., Parker, K., 2011. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, Eleventh Edition. McGraw Hill Professional.

Buabeng, K.O., Mackenzie, A.R., Laing, R.B., Cook, I., Jappy, B., Gould, I.M., 1999. Assessment of the efficacy, safety and quality of gentamicin use in Aberdeen Royal Infirmary. *J. Antimicrob. Chemother.* 44, 843–845.  
<https://doi.org/10.1093/jac/44.6.843>

Burdet, C., Pajot, O., Couffignal, C., Armand-Lefèvre, L., Foucrier, A., Laouénan, C., Wolff, M., Massias, L., Mentré, F., 2015. Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia. *Eur. J. Clin. Pharmacol.* 71, 75–83.  
<https://doi.org/10.1007/s00228-014-1766-y>

Burgess, D.S., 2005. Use of Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Treatment of *Pseudomonas aeruginosa* Infections. *Infect. Dis. Soc. Am. Clin. Infect. Dis.* 2005; 40:S99–104.

- Burton, M.E., 2006. *Applied Pharmacokinetics & Pharmacodynamics: Principles of Therapeutic Drug Monitoring*. Lippincott Williams & Wilkins.
- Burton, M.E., Schentag, J., 2006. *Applied Pharmacokinetics & Pharmacodynamics: Principles of Therapeutic Drug Monitoring*, fourth ed. Lippincott Williams & Wilkins., Philadelphia, PA.
- Cannon, J.G., 2006. Goodman and Gilman's *The Pharmacological Basis of Therapeutics*. 11th Edition Edited by Laurence Brunton, John Lazo, and Keith Parker. McGraw Hill, New York. 2005. xxiii + 2021 pp. 21 × 26 cm. ISBN 0-07-142280-3. *J. Med. Chem.* 49, 1222–1222. <https://doi.org/10.1021/jm058286b>
- Carcillo, J.A., Dean, J.M., Holubkov, R., Berger, J., Meert, K.L., Anand, K., Zimmerman, J., Newth, C.J., Harrison, R., Burr, J., Willson, D.F., Nicholson, C., Bell, M.J., Berg, R.A., Shanley, T.P., Heidemann, S.M., Dalton, H., Jenkins, T.L., Doctor, A., Webster, A., 2016. Inherent Risk Factors for Nosocomial Infection in the Long Stay Critically Ill Child Without Known Baseline Immunocompromise: A Post –Hoc Analysis of the CRISIS Trial. *Pediatr. Infect. Dis. J.* 35, 1182–1186. <https://doi.org/10.1097/INF.0000000000001286>
- Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R., 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J. Chronic Dis.* 40, 373–383. [https://doi.org/10.1016/0021-9681\(87\)90171-8](https://doi.org/10.1016/0021-9681(87)90171-8)
- Chaves, B.J., Tadi, P., 2020. Gentamicin, in: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- Clinical and Laboratory Standards Institute, 2018. *Performance Standards for Antimicrobial Susceptibility Testing*. 28th Ed.
- Cobussen, M., de Kort, J.M.L., Dennert, R.M., Lowe, S.H., Stassen, P.M., 2016. No increased risk of acute kidney injury after a single dose of gentamicin in patients with sepsis. *Infect. Dis. Lond. Engl.* 48, 274–280. <https://doi.org/10.3109/23744235.2015.1109136>
- Cobussen, M., Stassen, P.M., Posthouwer, D., van Tiel, F.H., Savelkoul, P.H.M., Havenith, T., Haeseker, M.B., 2019. Improving peak concentrations of a single dose regime of gentamicin in patients with sepsis in the emergency department. *PLoS ONE* 14. <https://doi.org/10.1371/journal.pone.0210012>
- Craig, W.A., 2011. Optimizing aminoglycoside use. *Crit. Care Clin.* 27, 107–121. <https://doi.org/10.1016/j.ccc.2010.11.006>
- Dahlan, M.P., 2016. *Besar sampel dalam penelitian kedokteran dan kesehatan*. Epidemiologi Indonesia, Jakarta.

- DiPiro, J.T., Talbert, R.L., Yee, G.C., Wells, B.G., Posey, L.M., 2014. *Pharmacotherapy A Pathophysiologic Approach 9/E*. McGraw Hill Professional.
- Djuwarno, E.N., 2014. Hasil Evaluasi Penggunaan Gentamisin Untuk Terapi Pneumonia Pada Pasien Geriatri Rawat Inap Di Rumah Sakit Umum Pusat Dr. Sardjito Yogyakarta. Universitas Gadjah Mada.
- Duszynska, W., Taccone, F.S., Hurkacz, M., Kowalska-Krochmal, B., Wiela-  
Hojeńska, A., Kübler, A., 2013. Therapeutic drug monitoring of amikacin  
in septic patients. *Crit. Care Lond. Engl.* 17, R165.  
<https://doi.org/10.1186/cc12844>
- El Halal, M.G. dos S., Barbieri, E., Filho, R.M., Trotta, E. de A., Carvalho,  
P.R.A., 2012. Admission source and mortality in a pediatric intensive care  
unit. *Indian J. Crit. Care Med. Peer-Rev. Off. Publ. Indian Soc. Crit. Care  
Med.* 16, 81–86. <https://doi.org/10.4103/0972-5229.99114>
- Endriastuti, N.E., 2014. Hasil Evaluasi Pendosisan Gentamisin Pada Pasien  
Pneumonia Berat Di Bangsal Anak Rawat Inap RSUP Dr. Sardjito  
Yogyakarta. Universitas Gadjah Mada.
- Engler, D., Schellack, N., Naude, A., Gous, A.G.S., 2013. Use of amikacin in  
neonates and related ototoxicity. *Prof. Nurs. Today* 17, 24–27.
- European Committee on Antimicrobial Susceptibility Testing (EUCAST), 2009.  
Gentamicin rationale for the EUCAST clinical breakpoints [WWW  
Document]. URL [https://eucast.org/clinical\\_breakpoints/](https://eucast.org/clinical_breakpoints/) (accessed  
8.18.20).
- Fauzi, R., 2018. Evaluasi Kesesuaian Penggunaan Antibiotik Pada Pasien Sepsis  
Di Neonatal Intensive Care Unit (Nicu) Dan Pediatric Intensive Care Unit  
(Picu) RSUP DR. Sardjito Yogyakarta. Universitas Gadjah Mada.
- Finch, R.G. (Ed.), 2010. *Antibiotic and chemotherapy: anti-infective agents and  
their use in therapy*, 9. ed. ed. Saunders/Elsevier, Edinburgh.
- Finch, R.G., Greenwood, D., Whitley, R.J., Norrby, S.R., 2010. *Antibiotic and  
Chemotherapy E-Book: Expert Consult*. Elsevier Health Sciences.
- Fukuoka, N., Aibiki, M., 2008. Recommended dose of arbekacin, an  
aminoglycoside against methicillin-resistant *Staphylococcus aureus*, does  
not achieve desired serum concentration in critically ill patients with  
lowered creatinine clearance. *J. Clin. Pharm. Ther.* 33, 521–527.  
<https://doi.org/10.1111/j.1365-2710.2008.00947.x>
- Gálvez, R., Luengo, C., Cornejo, R., Kosche, J., Romero, C., Tobar, E., Illanes,  
V., Llanos, O., Castro, J., 2011. Higher than recommended amikacin  
loading doses achieve pharmacokinetic targets without associated toxicity.  
*Int. J. Antimicrob. Agents* 38, 146–151.  
<https://doi.org/10.1016/j.ijantimicag.2011.03.022>

- Ghasemi, A., Azimzadeh, I., Afghan, M., Momenan, A.A., Bagheripour, F., Azizi, F., 2015. Pediatric reference values for serum creatinine and estimated glomerular filtration rate in Iranians: Tehran Lipid and Glucose Study. *Arch. Iran. Med.* 18, 753–759. <https://doi.org/0151811/AIM.005>
- Hakim, L., 2012. *Farmakokinetika klinik, Seri Farmasi Klinik.* Bursa Ilmu, Yogyakarta.
- Healy, F., Hanna, B.D., Zinman, R., 2012. Pulmonary Complications of Congenital Heart Disease. *Paediatr. Respir. Rev.* 13, 10–15. <https://doi.org/10.1016/j.prrv.2011.01.007>
- Hernández Ceruelos, A., Romero-Quezada, L.C., Ruvalcaba Ledezma, J.C., López Contreras, L., 2019. Therapeutic uses of metronidazole and its side effects: an update. *Eur. Rev. Med. Pharmacol. Sci.* 23, 397–401. [https://doi.org/10.26355/eurrev\\_201901\\_16788](https://doi.org/10.26355/eurrev_201901_16788)
- Horowitz, I.N., Tai, K., 2007. Hypoalbuminemia in critically ill children. *Arch. Pediatr. Adolesc. Med.* 161, 1048–1052. <https://doi.org/10.1001/archpedi.161.11.1048>
- Incáni, R.N., Hernández, M., Cortez, J., González, M.E., Salazar, Y.D., 2010. *Staphylococcus warneri* meningitis in a patient with *Strongyloides stercoralis* hyperinfection and lymphoma: first report of a case. *Rev. Inst. Med. Trop. Sao Paulo* 52, 169–170. <https://doi.org/10.1590/s0036-46652010000300011>
- Johnson, A.-W.B.R., Osinusi, K., Aderele, W.I., Gbadero, D.A., Olaleye, O.D., Adeyemi-Doro, F.A.B., 2008. Etiologic agents and outcome determinants of community-acquired pneumonia in urban children: a hospital-based study. *J. Natl. Med. Assoc.* 100, 370–385. [https://doi.org/10.1016/s0027-9684\(15\)31269-4](https://doi.org/10.1016/s0027-9684(15)31269-4)
- Kalil, A.C., Metersky, M.L., Klompas, M., Muscedere, J., Sweeney, D.A., Palmer, L.B., Napolitano, L.M., O’Grady, N.P., Bartlett, J.G., Carratalà, J., El Solh, A.A., Ewig, S., Fey, P.D., File, T.M., Restrepo, M.I., Roberts, J.A., Waterer, G.W., Cruse, P., Knight, S.L., Brozek, J.L., 2016. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* 63, e61–e111. <https://doi.org/10.1093/cid/ciw353>
- Kang, J.S., Lee, M.H., 2009. Overview of therapeutic drug monitoring. *Korean J. Intern. Med.* 24, 1–10. <https://doi.org/10.3904/kjim.2009.24.1.1>
- Katarnida, S.S., Karyanti, M.R., Oman, D.M., Katar, Y., 2016. Pola Sensitifitas Bakteri dan Penggunaan Antibiotik. *Sari Pediatri* 15, 122–6. <https://doi.org/10.14238/sp15.2.2013.122-6>

- Katzung, B., Masters, S., Trevor, A., 2009. *Basic and Clinical Pharmacology*, 11th Edition. Mcgraw-hill.
- Katzung, B.G., Masters, S.B., Trevor, A.J., 2009. *Basic and Clinical Pharmacology*, 11th Edition. McGraw Hill Professional.
- Kaur, G., Vinayak, N., Mittal, K., Kaushik, J.S., Aamir, M., 2014. Clinical outcome and predictors of mortality in children with sepsis, severe sepsis, and septic shock from Rohtak, Haryana: A prospective observational study. *Indian J. Crit. Care Med. Peer-Rev. Off. Publ. Indian Soc. Crit. Care Med.* 18, 437–441. <https://doi.org/10.4103/0972-5229.136072>
- Kaushal, R., Bates, D.W., Landrigan, C., McKenna, K.J., Clapp, M.D., Federico, F., Goldmann, D.A., 2001. Medication errors and adverse drug events in pediatric inpatients. *JAMA* 285, 2114–2120. <https://doi.org/10.1001/jama.285.16.2114>
- Kemendes RI, 2011. Peraturan Menteri Kesehatan Republik Indonesia Nomor 2406/MENKES/PER/XII/2011 tentang Pedoman Umum Penggunaan Antibiotik.
- Kementerian Kesehatan, 2014. Peraturan Menteri Kesehatan Republik Indonesia Nomor 27 Tahun 2014 Tentang Petunjuk Teknis Sistem Indonesia Case Base Groups (INA-CBGs). Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kementrian Kesehatan RI, 2019. Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/813/2019 Tentang Formularium Nasional 154.
- Kiel, Patrick J., Lo, M., Stockwell, D., Patel, G.P., 2008. An evaluation of amikacin nephrotoxicity in the hematology/oncology population. *Am. J. Ther.* 15, 131–136. <https://doi.org/10.1097/MJT.0b013e31815adfde>
- Kiel, Patrick J, Lo, M., Stockwell, D., Patel, G.P., 2008. An Evaluation of Amikacin Nephrotoxicity in the Hematology/Oncology Population: *Am. J. Ther.* 15, 131–136. <https://doi.org/10.1097/MJT.0b013e31815adfde>
- Kitano, Y., Wakatake, H., Saito, H., Tsutsumi, K., Yoshida, H., Yoshida, M., Takita, M., Yoshida, T., Masui, Y., Taira, Y., Fujitani, S., 2020. Clinical outcomes of urinary tract infection caused by extended spectrum beta-lactamase producing Enterobacteriaceae: a retrospective observational study comparing patients with and without systemic inflammatory response syndrome. *Acute Med. Surg.* 7, e472. <https://doi.org/10.1002/ams2.472>
- Kovačević, T., Avram, S., Milaković, D., Špirić, N., Kovačević, P., 2016. Therapeutic monitoring of amikacin and gentamicin in critically and noncritically ill patients. *J. Basic Clin. Pharm.* 7, 65–69. <https://doi.org/10.4103/0976-0105.183260>

- Kramer, A.A., Zimmerman, J.E., 2011. The relationship between hospital and intensive care unit length of stay. *Crit. Care Med.* 39, 1015–1022. <https://doi.org/10.1097/CCM.0b013e31820eabab>
- Krause, K.M., Serio, A.W., Kane, T.R., Connolly, L.E., 2016a. Aminoglycosides: An Overview. *Cold Spring Harb. Perspect. Med.* 6. <https://doi.org/10.1101/cshperspect.a027029>
- Krause, K.M., Serio, A.W., Kane, T.R., Connolly, L.E., 2016b. Aminoglycosides: An Overview. *Cold Spring Harb. Perspect. Med.* 6. <https://doi.org/10.1101/cshperspect.a027029>
- Kumar, V.A., Khan, S., 2015. Defining multidrug resistance in Gram-negative bacilli. *Indian J. Med. Res.* 141, 491–492. <https://doi.org/10.4103/0971-5916.159318>
- Lacy, M.K., Nicolau, D.P., Nightingale, C.H., Quintiliani, R., 1998. The pharmacodynamics of aminoglycosides. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* 27, 23–27. <https://doi.org/10.1086/514620>
- Lee, J.W., 2010. Fluid and electrolyte disturbances in critically ill patients. *Electrolyte Blood Press. E BP* 8, 72–81. <https://doi.org/10.5049/EBP.2010.8.2.72>
- Lexicomp, 2018. *Drug Information Handbook: A Clinically Relevant Resource for All Healthcare Professionals.* Wolters Kluwer.
- Li, H.K., Agweyu, A., English, M., Bejon, P., 2015. An Unsupported Preference for Intravenous Antibiotics. *PLoS Med.* 12. <https://doi.org/10.1371/journal.pmed.1001825>
- Lingvall, M., Reith, D., Broadbent, R., 2005. The effect of sepsis upon gentamicin pharmacokinetics in neonates. *Br. J. Clin. Pharmacol.* 59, 54–61. <https://doi.org/10.1111/j.1365-2125.2005.02260.x>
- Lopez-Novoa, J.M., Quiros, Y., Vicente, L., Morales, A.I., Lopez-Hernandez, F.J., 2011. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. *Kidney Int.* 79, 33–45. <https://doi.org/10.1038/ki.2010.337>
- Lugo, G., Castañeda-Hernández, G., 1997. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. *Crit. Care Med.* 25, 806–811. <https://doi.org/10.1097/00003246-199705000-00016>
- Mahmoudi, L., Mohammadpour, A.H., Ahmadi, A., Niknam, R., Mojtahedzadeh, M., 2013a. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients. *Eur. Rev. Med. Pharmacol. Sci.* 17, 285–291.

- Mahmoudi, L., Mohammadpour, A.H., Ahmadi, A., Niknam, R., Mojtahedzadeh, M., 2013b. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients. *Eur. Rev. Med. Pharmacol. Sci.* 17, 285–291.
- Mareville, J., Gay, J., Cliquennois, E., Herbaux, C., Pasquier, F., Allorge, D., Blondiaux, N., Berthon, C., Alfandari, S., 2012. Therapeutic drug monitoring of aminoglycosides in acute myeloid leukaemia patients. *Scand. J. Infect. Dis.* 44, 398–401. <https://doi.org/10.3109/00365548.2011.645868>
- Maulida, M., Prof. Dr. M. Kuswandi, S., Ratna Yuliani, M.B.S., 2016. Pola Resistensi Bakteri Terhadap Antibiotik Pada Penderita Sepsis Bayi Di Ruang Picu Dan Nicu RSUP Dr. Soeradji Tirtonegoro Klaten Periode Agustus 2013-Agustus 2015 (s1). Universitas Muhammadiyah Surakarta. <http://eprints.ums.ac.id/43323/10/LAMPIRAN.pdf>
- McEvoy, G.K., 2008. AHFS Drug information. Bethesda, Md. : American Society of Health-System Pharmacists, ©2008.
- McWilliam, S.J., Antoine, D.J., Smyth, R.L., Pirmohamed, M., 2017. Aminoglycoside-induced nephrotoxicity in children. *Pediatr. Nephrol. Berl. Ger.* 32, 2015–2025. <https://doi.org/10.1007/s00467-016-3533-z>
- Mohamed, A.F., Nielsen, E.I., Cars, O., Friberg, L.E., 2012. Pharmacokinetic-Pharmacodynamic Model for Gentamicin and Its Adaptive Resistance with Predictions of Dosing Schedules in Newborn Infants. *Antimicrob. Agents Chemother.* 56, 179–188. <https://doi.org/10.1128/AAC.00694-11>
- Moore, R.D., Smith, C.R., Lietman, P.S., 1984. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. *J. Infect. Dis.* 149, 443–448. <https://doi.org/10.1093/infdis/149.3.443>
- Nangalu, R., Pooni, P.A., Bhargav, S., Bains, H.S., 2016. Impact of malnutrition on pediatric risk of mortality score and outcome in Pediatric Intensive Care Unit. *Indian J. Crit. Care Med. Peer-Rev. Off. Publ. Indian Soc. Crit. Care Med.* 20, 385–390. <https://doi.org/10.4103/0972-5229.186218>
- Naughton, C.A., 2008. Drug-Induced Nephrotoxicity. *Am. Fam. Physician* 78, 743–750.
- Nicolau, D.P., Freeman, C.D., Belliveau, P.P., Nightingale, C.H., Ross, J.W., Quintiliani, R., 1995. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. *Antimicrob. Agents Chemother.* 39, 650–655. <https://doi.org/10.1128/aac.39.3.650>
- Oshima, T., Kodama, Y., Takahashi, W., Hayashi, Y., Iwase, S., Kurita, T., Saito, D., Yamaji, Y., Oda, S., 2016. Empiric Antibiotic Therapy for Severe

- Sepsis and Septic Shock. *Surg. Infect.* 17, 210–216.  
<https://doi.org/10.1089/sur.2014.096>
- PDPI, 2003. *Pneumonia Nosokomial, Pedoman Diagnosis dan Penatalaksanaan di Indonesia*. Balai Penerbit FK UI, Jakarta, Indonesia.
- Pe, M., J, L., S, K., J, S., 1991. A prospective randomized study comparing once-versus twice-daily amikacin dosing in critically ill adult and paediatric patients. *J. Antimicrob. Chemother.* 28, 753–764.  
<https://doi.org/10.1093/jac/28.5.753>
- Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., Raunio, H., 2008. Inhibition and induction of human cytochrome P450 enzymes: current status. *Arch. Toxicol.* 82, 667–715.  
<https://doi.org/10.1007/s00204-008-0332-8>
- Picard, W., Bazin, F., Clouzeau, B., Bui, H.-N., Soulat, M., Guilhon, E., Vargas, F., Hilbert, G., Bouchet, S., Gruson, D., Moore, N., Boyer, A., 2014. Propensity-Based Study of Aminoglycoside Nephrotoxicity in Patients with Severe Sepsis or Septic Shock. *Antimicrob. Agents Chemother.* 58, 7468–7474. <https://doi.org/10.1128/AAC.03750-14>
- Pichala, P.T., Kumar, B.M., Zachariah, S., Thomas, D., Saunchez, L., Gerardo, A.-U., 2013. An interventional study on intensive care unit drug therapy assessment in a rural district hospital in India. *J. Basic Clin. Pharm.* 4, 64–67. <https://doi.org/10.4103/0976-0105.118801>
- Pinder, M., Bellomo, R., Lipman, J., 2002. Pharmacological principles of antibiotic prescription in the critically ill. *Anaesth. Intensive Care* 30, 134–144. <https://doi.org/10.1177/0310057X0203000203>
- Pollack, M.M., Holubkov, R., Reeder, R., Dean, J.M., Meert, K.L., Berg, R.A., Newth, C.J.L., Berger, J.T., Harrison, R.E., Carcillo, J., Dalton, H., Wessel, D.L., Jenkins, T.L., Tamburro, R., 2018. Pediatric Intensive Care Unit (PICU) Length of Stay: Factors Associated with Bed Utilization and Development of a Benchmarking Model. *Pediatr. Crit. Care Med. J. Soc. Crit. Care Med. World Fed. Pediatr. Intensive Crit. Care Soc.* 19, 196–203.  
<https://doi.org/10.1097/PCC.0000000000001425>
- Pratiwi, T.A., 2018. *Evaluasi Pendosisan Aminoglikosida Terhadap Efektivitas Dan Fungsi Ginjal Pada Pasien Dengan Gangguan Ginjal Kronis*. Universitas Gadjah Mada.
- Purwati, N., 2016. Klasifikasi Status Gizi Balita Berdasarkan Indeks Antropometri Bb/U Dan Bb/Tb Menggunakan Algoritma Backpropagation. *IJNS - Indones. J. Netw. Secur.* 5.  
<https://doi.org/10.1123/ijns.v5i4.1436>
- Roberts, J.A., Lipman, J., 2006. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Clin. Pharmacokinet. 45, 755–773. <https://doi.org/10.2165/00003088-200645080-00001>

- Ruiz, J., Ramirez, P., Company, M.J., Gordon, M., Villarreal, E., Concha, P., Aroca, M., Frasquet, J., Remedios-Marqués, M., Castellanos-Ortega, Á., 2018. Impact of amikacin pharmacokinetic/pharmacodynamic index on treatment response in critically ill patients. *J. Glob. Antimicrob. Resist.* 12, 90–95. <https://doi.org/10.1016/j.jgar.2017.09.019>
- Rumah Sakit Umum Pusat Dr. Sardjito, 2011. Pedoman Penggunaan Antibiotik RSUP Dr. Sardjito, Yogyakarta.
- Russell, A.B., Sharland, M., Heath, P.T., 2012. Improving antibiotic prescribing in neonatal units: time to act. *Arch. Dis. Child. Fetal Neonatal Ed.* 97, F141-146. <https://doi.org/10.1136/adc.2007.120709>
- Ryoo, S.M., Kang, G.H., Shin, T.G., Hwang, S.Y., Kim, K., Jo, Y.H., Park, Y.S., Choi, S.-H., Yoon, Y.H., Kwon, W.Y., Suh, G.J., Lim, T.H., Han, K.S., Choi, H.S., Chung, S.P., Kim, W.Y., 2018. Clinical outcome comparison of patients with septic shock defined by the new sepsis-3 criteria and by previous criteria. *J. Thorac. Dis.* 10, 845–853. <https://doi.org/10.21037/jtd.2018.01.96>
- Shaddock, E.J., Feldman, C., 2016. Shorter antibiotic courses in community-acquired pneumonia—ready for prime time. *J. Thorac. Dis.* 8, E1628–E1631. <https://doi.org/10.21037/jtd.2016.12.52>
- Shahrami, B., Najmeddin, F., Rouini, M.R., Najafi, A., Sadeghi, K., Amini, S., Kheznia, S.S., Sharifnia, H.R., Mojtahedzadeh, M., 2020. Evaluation of Amikacin Pharmacokinetics in Critically Ill Patients with Intra-abdominal Sepsis. *Adv. Pharm. Bull.* 10, 114–118. <https://doi.org/10.15171/apb.2020.014>
- Singer, M., Deutschman, C.S., Seymour, C.W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G.R., Chiche, J.-D., Coopersmith, C.M., Hotchkiss, R.S., Levy, M.M., Marshall, J.C., Martin, G.S., Opal, S.M., Rubenfeld, G.D., van der Poll, T., Vincent, J.-L., Angus, D.C., 2016. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 315, 801. <https://doi.org/10.1001/jama.2016.0287>
- Siraj, S., 2012. Therapeutic Drug Monitoring of Selected Drugs: An Approach to Drug Therapy Optimization. (doctoral). J.S.S. College of Pharmacy, Ootacamund.
- Soegijanto, S., 2010. Kumpulan makalah penyakit tropis dan infeksi di Indonesia. Airlangga University Press.
- Sugiyono, 2011. Metode Penelitian Kuantitatif Kualitatif DAN R&D (cetakan ke-14). Alfabeta, Bandung.

- Sweetman, S.C., 2009. Martindale: the complete drug reference [book + CD-ROM], 36th ed. Pharmaceutical Press.
- Taccone, F.S., Laterre, P.-F., Spapen, H., Dugernier, T., Delattre, I., Layeux, B., De Backer, D., Wittebole, X., Wallemacq, P., Vincent, J.-L., Jacobs, F., 2010a. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. *Crit. Care Lond. Engl.* 14, R53. <https://doi.org/10.1186/cc8945>
- Taccone, F.S., Laterre, P.-F., Spapen, H., Dugernier, T., Delattre, I., Layeux, B., De Backer, D., Wittebole, X., Wallemacq, P., Vincent, J.-L., Jacobs, F., 2010b. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. *Crit. Care Lond. Engl.* 14, R53. <https://doi.org/10.1186/cc8945>
- Tai, D., Dick, P., To, T., Wright, J.G., 2006. Development of pediatric comorbidity prediction model. *Arch. Pediatr. Adolesc. Med.* 160, 293–299. <https://doi.org/10.1001/archpedi.160.3.293>
- Thakur, K.T., Motta, M., Asemota, A.O., Kirsch, H.L., Benavides, D.R., Schneider, E.B., McArthur, J.C., Geocadin, R.G., Venkatesan, A., 2013. Predictors of outcome in acute encephalitis. *Neurology* 81, 793–800. <https://doi.org/10.1212/WNL.0b013e3182a2cc6d>
- Tiwari, L.K., Singhi, S., Jayashree, M., Baranwal, A.K., Bansal, A., 2014. Hypoalbuminemia in critically sick children. *Indian J. Crit. Care Med. Peer-Rev. Off. Publ. Indian Soc. Crit. Care Med.* 18, 565–569. <https://doi.org/10.4103/0972-5229.140143>
- Tjay, T.H., Rahardja, K., 2007. Obat-obat penting: khasiat, penggunaan dan efek-efek sampingnya. Elex Media Komputindo.
- Torres-Espíndola, L.M., Demetrio-Ríos, J., Carmona-Aparicio, L., Galván-Díaz, C., Pérez-García, M., Chávez-Pacheco, J.L., Granados-Montiel, J., Torres-Ramírez de Arellano, I., Aquino-Gálvez, A., Castillejos-López, M.D.J., 2019. Comorbidity Index as a Predictor of Mortality in Pediatric Patients With Solid Tumors. *Front. Pediatr.* 7. <https://doi.org/10.3389/fped.2019.00048>
- Turnidge, J., 2003. Pharmacodynamics and dosing of aminoglycosides. *Infect. Dis. Clin. North Am.* 17, 503–528, v.
- Uranga, A., España, P.P., Bilbao, A., Quintana, J.M., Arriaga, I., Intxausti, M., Lobo, J.L., Tomás, L., Camino, J., Nuñez, J., Capelastegui, A., 2016. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. *JAMA Intern. Med.* 176, 1257–1265. <https://doi.org/10.1001/jamainternmed.2016.3633>

- Van Eldere, J., 2003. Multicentre surveillance of *Pseudomonas aeruginosa* susceptibility patterns in nosocomial infections. *J. Antimicrob. Chemother.* 51, 347–352. <https://doi.org/10.1093/jac/dkg102>
- van 't Veen, A., van der Zee, A., Nelson, J., Speelberg, B., Kluytmans, J.A.J.W., Buiting, A.G.M., 2005. Outbreak of Infection with a Multiresistant *Klebsiella pneumoniae* Strain Associated with Contaminated Roll Boards in Operating Rooms. *J. Clin. Microbiol.* 43, 4961–4967. <https://doi.org/10.1128/JCM.43.10.4961-4967.2005>
- Veranan, T.A., 2016. Hubungan Antara Usia Dan Jenis Kelamin Dengan Kesembuhan Pasien di ICU Rumah Sakit Haji Adam Malik Medan Periode Juli – Oktober 2014.
- Vincent, J.-L., Rello, J., Marshall, J., Silva, E., Anzueto, A., Martin, C.D., Moreno, R., Lipman, J., Gomersall, C., Sakr, Y., Reinhart, K., EPIC II Group of Investigators, 2009. International study of the prevalence and outcomes of infection in intensive care units. *JAMA* 302, 2323–2329. <https://doi.org/10.1001/jama.2009.1754>
- Wells, B.G., DiPiro, J.T., Schwinghammer, T.L., DiPiro, C.V., 2015. *Pharmacotherapy Handbook, 9/E*. McGraw Hill Professional.
- Winter, M.E., 2004a. *Basic Clinical Pharmacokinetics, fourth. ed.* Lippincott Williams & Wilkins.
- Winter, M.E., 2004b. *Basic Clinical Pharmacokinetics*. Lippincott Williams & Wilkins.
- Zimmerman, J.J., 2015. Pediatric Sepsis From Start to Finish. *Pediatr. Crit. Care Med. J. Soc. Crit. Care Med. World Fed. Pediatr. Intensive Crit. Care Soc.* 16, 479–480. <https://doi.org/10.1097/PCC.0000000000000389>